Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trifluoperazine for hospitalized patients with COVID-19
IRCT20200408046992N1Phase 3Completed
- Sponsor
- Vice Chancellor for Research, Birjand University of Medical Sciences
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of trifluoperazine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Vice Chancellor for Research, Birjand University of Medical Sciences. Primary endpoints: Respiratory function of the lungs, Reduction of inflammatory responses and 2 more. Started Apr 2020; status: completed.
02
Drugs
trifluoperazine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200408046992N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200408046992N1.